Intec Pharma (Israel) Valuation Overview

NTEC -- Israel Stock  

null 1,495  5.00  0.34%

Intec Pharma regular Real Value cannot be determined due to lack of data. The prevalent price of Intec Pharma is 1495.0. Based on Macroaxis valuation methodology, the corporation cannot be evaluated at this time. Macroaxis calculates value of Intec Pharma from evaluating the corporation fundamentals such as Price to Book of 805.45times, Return On Asset of (41.22)% and Return On Equity of (98.29)% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.
Horizon     30 Days    Login   to change
Intec Pharma Ltd is considered to be number one stock in price to book category among related companies. It is considered to be number one stock in beta category among related companies . The ratio of Price to Book to Beta for Intec Pharma Ltd is about  781.99 

Current Market Valuation

Intec Pharma Valuation Boundaries

Not valued
October 23, 2018
1,495
Market Value
0.00
Real Value
Target Odds
  
0.00
Upside
Intec Pharma is Unknown risk asset. Calculation of real value of Intec Pharma is based on 1 month time horizon. Increasing Intec Pharma time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Please see also Stocks Correlation. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.
Search macroaxis.com